Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.19 | N/A | +17.39% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.19 | N/A | +17.39% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter. They emphasized a commitment to improving operational performance.
Management did not provide specific guidance for future quarters.
The company is focusing on its pipeline and operational efficiencies.
The earnings report indicates that Biocryst Pharmaceuticals is still facing challenges, particularly in generating revenue. The stock's significant drop of 40.35% reflects investor concerns about the company's future performance and lack of guidance. The positive surprise in EPS may not have been enough to offset worries about revenue and overall strategy.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
INTERCONTINENTAL EXC
Nov 5, 2012